References
- Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–281.
- Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310(9):948–959.
- Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362(12):1090–1101.
- American Diabetes A. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S73–S85.
- Society CD. Guidelines for the prevention and treatment of type 2 diabetes in China (2017 Edition). Chin J Diabetes Mellitus. 2018;1:4–67.
- Society CD. Guidelines for the prevention and treatment of type 2 diabetes in China (2013 Edition). Chin J Endocrinol Metab. 2014;10:839–942.
- American Diabetes A. Standards of medical care in diabetes–2009. Diabetes Care. 2009;32(Suppl 1):S13–S61.
- Ahren B. Glucagon-like peptide-1 receptor agonists for type 2 diabetes: a rational drug development. J Diabetes Investig. 2018;10:196–201.
- McCarty D, Coleman M, Boland CL. Lixisenatide: a new daily GLP-1 agonist for type 2 diabetes management. Ann Pharmacother. 2017;51(5):401–409.
- Rosenstock J, Guerci B, Hanefeld M, et al. Prandial options to advance basal insulin glargine therapy: testing lixisenatide plus basal insulin versus insulin glulisine either as basal-plus or basal-bolus in type 2 diabetes: the GetGoal duo-2 trial. Diabetes Care. 2016;39(8):1318–1328.
- Afonso M, Ryan F, Pitcher A, et al. Evaluating drug cost per responder and number needed to treat associated with lixisenatide on top of glargine when compared to rapid-acting insulin intensification regimens on top of glargine, in patients with type 2 diabetes in the UK, Italy, and Spain. J Med Econ. 2017;20(6):633–639.
- National Bureau of Statistics of China. Statistical Communiqué of the People's Republic of China on the 2018 National Economic and Social Development. http://www.stats.gov.cn/english/PressRelease/201902/t20190228_1651335.html
- Moreira RO, Cobas R, Lopes Assis Coelho RC. Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes? Diabetol Metab Syndr. 2018;10(1):26.
- Seino Y, Min KW, Niemoeller E, et al. Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab. 2012;14(10):910–917.
- Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care. 2013;36(9):2489–2496.
- Charbonnel B, Bertolini M, Tinahones FJ, et al. Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis. J Diabetes Complicat. 2014;28(6):880–886.
- Raccah D, Lin J, Wang E, et al. Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials. J Diabetes Complicat. 2014;28(1):40–44.
- Yang W, Min K, Zhou Z, et al. Efficacy and safety of lixisenatide in a predominantly Asian population with type 2 diabetes insufficiently controlled with basal insulin: The GetGoal-L-C randomized trial. Diabetes Obes Metab. 2018;20(2):335–343.
- Huetson P, Palmer JL, Levorsen A, et al. Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway. J Med Econ. 2015;18(8):573–585.